Evaluation and treatment of male and female pattern hair loss

  • Elise A. Olsen
    Correspondence
    Correspondence to: Elise A. Olsen, MD, Professor of Medicine, Duke University Medical Center, Box 3294, Durham, North Carolina 27710.
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Andrew G. Messenger
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Jerry Shapiro
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Wilma F. Bergfeld
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Maria K. Hordinsky
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Janet L. Roberts
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Dow Stough
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • Ken Washenik
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
  • David A. Whiting
    Affiliations
    From the Duke University Medical Center,a Royal Hallamshire Hospital,b University of British Columbia,c Cleveland Clinic,d University of Minnesota,e Oregon Health and Science University,f The Stough Clinic,g Bosley Medical Institute and New York University School of Medicine,h and the Baylor Hair Research and Treatment Centeri USA
    Search for articles by this author
Published:November 25, 2004DOI:https://doi.org/10.1016/j.jaad.2004.04.008
      Twenty years ago, there were neither specific treatments available for pattern hair loss nor full understanding of the pathophysiology of this common disorder. Male pattern hair loss (MPHL) [or androgenetic alopecia (AGA), male pattern baldness (MPB)] had been clearly recognized as an androgen-dependent hereditary disorder since the 1940s.
      • Hamilton J.B.
      Male hormone stimulation is prerequisite and an incitant in common baldness.
      The principle of donor dominance was first appreciated at that time and led to the development of hair transplantation as a form of treatment.

      Orentreich N. Autografts in alopecias and other selected dermatological conditions. In: St. Whitelock OV, Furness FN, White EW, Lubowe II editors. Hair Growth and Hair Restoration. Ann NY Acad Sci 1959;83:463-79.

      However, it was not until recognition of the phenotype of individuals with the genetic deficiency of 5α-reductase (5αR),
      • Imperato-McGinley J.
      • Guerrero L.
      • Gautier T.
      • Peterson R.E.
      Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
      the isolation of the two isoforms of 5α-reductase (5αR-1 and 5αR-2),
      • Andersson S.
      • Berman D.M.
      • Jenkins E.P.
      • Russell D.W.
      Deletion of steroid 5-alpha-reductase 2 gene in male pseudohermaphroditism.
      • Jenkins E.P.
      • Andersson S.
      • Imperato-McGinley J.
      • Wilson J.D.
      • Russell D.W.
      Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase.
      along with the documented utility of 5α-reductase inhibitors in male pattern baldness,
      • Kaufman K.D.
      • Olsen E.A.
      • Whiting D.
      • Savin R.
      • DeVillez R.
      • Bergfeld W.
      Finasteride in the treatment of men with androgenetic alopecia.
      that the essential role of dihydrotestosterone (DHT) in male pattern hair loss was clearly established.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hamilton J.B.
        Male hormone stimulation is prerequisite and an incitant in common baldness.
        Am J Anat. 1942; 71: 451-480
      1. Orentreich N. Autografts in alopecias and other selected dermatological conditions. In: St. Whitelock OV, Furness FN, White EW, Lubowe II editors. Hair Growth and Hair Restoration. Ann NY Acad Sci 1959;83:463-79.

        • Imperato-McGinley J.
        • Guerrero L.
        • Gautier T.
        • Peterson R.E.
        Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
        Science. 1974; 186: 1213-1215
        • Andersson S.
        • Berman D.M.
        • Jenkins E.P.
        • Russell D.W.
        Deletion of steroid 5-alpha-reductase 2 gene in male pseudohermaphroditism.
        Nature. 1991; 354: 159-161
        • Jenkins E.P.
        • Andersson S.
        • Imperato-McGinley J.
        • Wilson J.D.
        • Russell D.W.
        Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase.
        J Clin Invest. 1992; 89: 293-300
        • Kaufman K.D.
        • Olsen E.A.
        • Whiting D.
        • Savin R.
        • DeVillez R.
        • Bergfeld W.
        Finasteride in the treatment of men with androgenetic alopecia.
        J Am Acad Dermatol. 1998; 39: 578-589
        • Hamilton J.B.
        Patterned loss of hair in man: Types and incidence.
        Ann NY Acad Sci. 1951; 53: 708-728
        • Birch M.P.
        • Messenger A.G.
        Genetic factors predispose to balding and non-balding in men.
        Eur J Dermatol. 2001; 11: 309-314
        • Muller S.A.
        Alopecia. Syndromes of genetic significance.
        J Invest Dermatol. 1973; 60: 475-492
        • Hamilton J.B.
        Age, sex, and genetic factors in the regulation of hair growth in man: A comparison of Caucasian and Japanese populations.
        in: Montaagna W. Ellis R.A. The Biology of Hair Growth. Academic Press, New York1958: 399-433
        • Setty L.R.
        Hair patterns of the scalp of white and Negro males.
        Am J Phys Antropol. 1970; 33: 49-55
        • Buechner H.A.
        • Brown M.
        • Tretola R.J.
        Baldness and emphysema.
        J La State Med Soc. 1964; 115: 329-332
        • Griffin J.E.
        • Wilson J.D.
        The androgen resistence syndromes: 5α-reductase deficiency, testicular feminization and related syndromes.
        in: Scrivér C.R. Beaudet A.L. Sly W.S. Valle D. The Metabolic Basis of Inherited Disease. 6th ed. McGraw-Hill, New York1989: 1919-1944
        • Jahoda C.A.
        • Reynolds A.J.
        Dermal-epidermal interactions. Adult follicle-derived cell populations and hair growth.
        Dermatol Clin. 1996; 14: 573-583
        • Van Scott E.J.
        • Ekel T.M.
        Geometric relationships between the matrix of the hair bulb and its dermal papilla in normal and alopecic scalp.
        J Invest Dermatol. 1958; 31: 281-287
        • Ibrahim L.
        • Wright E.A.
        A quantitative study of hair growth using mouse and rat vibrissal follicles. I. Dermal papilla volume determines hair volume.
        J Embryol Exp Morphol. 1982; 72: 209-224
        • Elliott K.
        • Stephenson T.J.
        • Messenger A.G.
        Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses.
        J Invest Dermatol. 1999; 113: 873-877
        • Choudhry R.
        • Hodgins M.B.
        • Van der Kwast T.H.
        • Brinkmann A.O.
        • Boersma W.J.
        Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands.
        J Endocrinol. 1992; 133: 467-475
        • Itami S.
        • Kurata S.
        • Sonoda T.
        • Takayasu S.
        Interaction between dermal papilla cells and follicular epithelial cells in vitro: effect of androgen.
        Br J Dermatol. 1995; 132: 527-532
        • Asada Y.
        • Sonoda T.
        • Ojiro M.
        • Kurata S.
        • Sato T.
        • Ezaki T.
        • et al.
        5 alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro.
        J Clin Endocrinol Metab. 2001; 86: 2875-2880
        • Küster W.
        • Happle R.
        The inheritance of common baldness: two B or not two B?.
        J Am Acad Dermatol. 1984; 11: 921-926
        • Ellis J.A.
        • Stebbing M.
        • Harrap S.B.
        Genetic analysis of male pattern baldness and the 5 alpha-reductase genes.
        J Invest Dermatol. 1998; 110: 849-853
        • Carey A.H.
        • Chan K.L.
        • Short F.
        • White D.
        • Williamson R.
        • Franks S.
        Evidence for a single gene effect causing polycystic ovaries and male pattern baldness.
        Clin Endocrinol. 1993; 38: 653-658
        • Ellis J.A.
        • Stebbing M.
        • Harrap S.B.
        Polymorphism of the androgen receptor gene is associated with male pattern baldness.
        J Invest Dermatol. 2001; 116: 452-455
        • Birch M.P.
        • Messenger J.F.
        • Messenger A.G.
        Hair density, hair diameter and the prevalence of female pattern hair loss.
        Br J Dermatol. 2001; 144: 297-304
        • Olsen E.A.
        Female pattern hair loss.
        J Am Acad Dermatol. 2001; 45: S70-S80
        • Futterweit M.D.
        • Dunaif A.
        • Yeh H.-C.
        • Kingsley P.
        The prevalence of hyperandrogenism in 109 consecutive female patients with difuse alopecia.
        J Am Acad Dermatol. 1988; 19: 831-836
        • Shum K.W.
        • Cullen D.R.
        • Messenger A.G.
        Hair loss in women with hyperandrogenism: four cases responding to finasteride.
        J Am Acad Dermatol. 2002; 47: 733-739
        • Vexiau P.
        • Chaspoux C.
        • Boudou P.
        • Fiet J.
        • Jouanique C.
        • Hardy N.
        • et al.
        Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.
        Br J Dermatol. 2002; 146: 992-999
        • Norwood O.T.
        • Lehr B.
        Female androgenetic alopecia: a separate entity.
        Dermatol Surg. 2000; 26: 679-682
        • Price V.H.
        • Roberts J.L.
        • Hordinsky M.
        • Olsen E.A.
        • Savin R.
        • Bergfeld W.
        • et al.
        Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
        J Am Acad Dermatol. 2000; 43: 768-776
        • Courtois M.
        • Loussouarn G.
        • Hourseau C.
        • Grollier J.F.
        Ageing and hair cycles.
        Br J Dermatol. 1995; 132: 86-93
        • Olsen E.A.
        Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss.
        J Am Acad Dermatol. 2003; 48: 253-262
        • Norwood O.T.
        Male pattern baldness: Classification and incidence.
        South Med J. 1975; 68: 1359-1365
        • Zinkernagel M.S.
        • Trueb R.M.
        Fibrosing alopecia in a pattern distribution.
        Arch Dermatol. 2000; 136: 205-211
        • Lesko S.M.
        • Rosenberg L.
        • Shapiro S.
        A case-control study of baldness in relation to myocardial infarction in men.
        JAMA. 1993; 269: 9987-10003
        • Lotufo P.A.
        • Chae C.U.
        • Ajani U.A.
        • Hennekens C.H.
        • Manson J.E.
        Male pattern baldness and coronary heart disease: The Physician's Health Study.
        Arch Intern Med. 2000; 150: 154-171
        • Ludwig E.
        Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.
        Br J Dermatol. 1977; 97: 247-254
        • Olsen E.A.
        The midline part: An important physical clue to the clinical diagnosis of androgenetic alopecia in women.
        J Am Acad Dermatol. 1999; 40: 106-109
        • Torley D.
        • Bellus G.A.
        • Munro C.S.
        Genes, growth factors and acanthosis nigricans.
        Br J Dermatol. 2002; 147 ({Review}): 1096-1100
        • Smith M.A.
        • Wells R.S.
        Male-type alopecia, alopecia areata, and normal hair in women: Family histories.
        Arch Dermatol. 1964; 89: 95-98
        • Rushton D.H.
        • Ramsay I.D.
        The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women.
        Clin Endocrinol. 1992; 36: 421-427
        • Freinkel R.K.
        • Freinkel N.
        Hair growth and alopecia in hypothyroidism.
        Arch Dermatol. 1972; 106: 349-352
        • Hård S.
        Non-anemic iron deficiency as an etiologic factor in diffuse loss of hair of the scalp in women.
        Acta Derm Venereol. 1963; 43: 562-569
        • Fairbanks V.F.
        • Beutler E.
        Erythrocyte disorders: Anemias related to disturbances of hemoglobin synthesis.
        in: Williams W.J. Beutler E. Erslev A.J. Lichtman M.A. Hematology. 4th ed. McGraw-Hill, New York1990: 482-505
        • Mestman J.H.
        • Anderson G.V.
        • Nelson D.H.
        Adrenal-pituitary responsiveness during therapy with an oral contraceptive.
        Obstet Gynecol. 1968; 31: 378-386
        • Pittaway D.E.
        Neoplastic causes of hyperandrogenism.
        Infertil Reprod Med Clin North Am. 1991; 2: 479-494
        • Azziz R.
        • Zacur H.A.
        21-Hydroxylase deficiency in female hyperandrogenism: Screening and diagnosis.
        J Clin Endocrinol Metab. 1989; 69: 577-584
        • Whiting D.A.
        Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.
        J Am Acad Dermatol. 1993; 28: 755-763
        • Sperling L.C.
        • Lupton G.P.
        Histopathology on non-scarring alopecia.
        J Cutan Pathol. 1995; 22: 97-114
        • Lattanand A.
        • Johnson W.C.
        Male pattern alopecia: A histopathologic and histochemical study.
        J Cutan Pathol. 1975; 2: 58-70
        • Whiting D.A.
        • Waldstreicher J.
        • Sanchez M.
        • Kaufman K.D.
        Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies. Results of finasteride 1 mg treatment of men and postmenopausal women.
        J Invest Dermatol Symp Proc. 1999; 4: 282-284
        • Whiting D.A.
        Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia.
        Dermatol Ther. 1998; 8: 24-33
        • Drake L.
        • Hordinsky M.
        • Fiedler V.
        • Swinehart J.
        • Unger W.P.
        • Cotterill P.C.
        • et al.
        The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
        J Am Acad Dermatol. 1999; 41: 550-554
        • Whiting D.A.
        • Olsen E.A.
        • Savin R.
        • Halper L.
        • Swinehart J.
        • Unger W.P.
        • Cotterill P.C.
        • Rodgers A.
        • et al.
        Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss.
        Eur J Dermatol. 2003; 13: 150-160
        • The Finasteride Male Pattern Hair Loss Study Group
        Long term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.
        Eur J Dermatol. 2002; 12: 38-49
      2. Physicians' Desk Reference.
        5th Edition. Thomson PDR, Montvale, NJ2003 (56)
        • Guess H.A.
        • Gormley G.J.
        • Stoner E.
        • Oeserling J.E.
        The effect of finasteride on prostate specific antigen: review of available data.
        J Urol. 1992; 155: 3-9
        • Oesterling J.E.
        • Roy J.
        • Agha A.
        • Shown T.
        • Krarup T.
        • Johansen T.
        • et al.
        Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride.
        Urol. 1997; 50: 13-18
        • Thompson I.M.
        • Goodman P.J.
        • Tagen C.M.
        • Lucia M.S.
        • Miller G.J.
        • Ford L.G.
        • et al.
        The influence of finasteride on the development of prostate cancer.
        N Engl J Med. 2003; 349: 213-222
        • Buhl A.E.
        • Conrad S.J.
        • Waldon D.J.
        • Brunden M.N.
        Potassium channel conductance as a control mechanism in hair follicles.
        J Invest Dermatol. 1991; 96: 735-745
        • Olsen E.A.
        • Dunlap F.E.
        • Funicella T.
        • Koperski J.A.
        • Swinehart J.M.
        • Tschen E.H.
        • et al.
        A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
        J Am Acad Dermatol. 2002; 47: 377-385
        • Price V.H.
        • Menefee E.
        • Strauss P.C.
        Changes in hair weight and hair count in men with androgenetic alopecia after application of 5% and 2% topical minoxidil, placebo, or no treatment.
        J Am Acad Dermatol. 1999; 41: 717-721
        • Olsen E.A.
        • Weiner M.S.
        Topical minoxidil in male pattern baldness: Effects of discontinuation of treatment.
        J Am Acad Dermatol. 1987; 17: 97-101
        • Diani A.R.
        • Mulholland M.J.
        • Shull K.L.
        • Kubicek M.F.
        • Johnson G.A.
        • Schostarez H.J.
        • et al.
        Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque.
        J Clin Endocrinol Metab. 1992; 74: 345-350
        • DeVillez R.I.
        • Jacobs J.P.
        • Szpunar C.A.
        • Warner M.L.
        Androgenetic alopecia in the female: Treatment with 2% topical minoxidil solution.
        Arch Dermatol. 1994; 130: 303-307
        • Lucky A.W.
        • Piacquadio D.J.
        • Ditre C.M.
        • Dunlap F.
        • Dunlap F.
        • Kantor I.
        • Pandya A.G.
        • et al.
        A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
        J Am Acad Dermatol. 2004; 50: 541-553
      3. Dorland's Medical Dictionary.
        26th Edition. W.B. Saunders Company, Philadelphia1985
        • Burke B.M.
        • Cunliffe W.J.
        Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.
        Br J Dermatol. 1985; 112 ([Letter]): 124-125
        • Dawber R.P.R.
        • Sonnex T.
        • Ralfs I.
        Oral anti-androgen treatment of common baldness in women.
        Br J Dermatol. 1982; 107: 20
        • Moltz L.
        • Mechies J.
        • Hammerstain J.
        Die Kontrazeptive Betreuung Androgenisiierter Frauen mit Einen Niedrig Dosierten Cyproteronacetathaltigen Eimphasempraparat.
        Dtsch Med Wochenschr. 1979; 104: 1376-1382
        • Stough D.
        Hair replacement. Surgical and medical.
        Mosby, St. Louis1996
        • Bernstein R.M.
        • Rassman W.R.
        Follicular transplantation: Patient evaluation and surgical planning.
        Dermatol Surg. 1997; 23: 771-784
        • Unger W.P.
        • Unger R.H.
        Hair transplanting: an important but often forgotten treatment for female pattern hair loss.
        J Am Acad Dermatol. 2003; 49: 853-860